Key result
Melatonin reduced doxorubicin-induced malondialdehyde elevation and morphological heart damage in rats.
Why the study?
Does melatonin reduce doxorubicin-induced cardiotoxicity (lipid peroxidation and morphological damage) in rats?
Does melatonin reduce doxorubicin-induced cardiotoxicity (lipid peroxidation and morphological damage) in rats?
Both physiological and pharmacological concentrations of melatonin protect the rat heart from doxorubicin-induced lipid peroxidation and morphological damage.
Answers are grounded in this paper and cite their sources.
Melatonin attenuates doxorubicin cardiotoxicity in rats; hypothesis-generating and leaves open translation to clinical cardioprotection.
Doxorubicin (Dox) is a widely used antineoplastic drug. Oxygen radical-induced injury of membrane lipids is considered to be the most important factor responsible for the development of Dox-induced cardiotoxicity. The pineal secretory product, melatonin, is known to be a potent free radical scavenger and its pharmacological concentrations have been shown to reduce Dox-induced cardiac damage. However, the physiological role of melatonin in the prevention of this damage is unknown. We investigated physiological and pharmacological effects of melatonin on Dox-induced changes in the levels of malondialdehyde (MDA), a lipid peroxidation product, and morphological changes in heart. Rats were pinealectomized (Px) or sham-operated (control) 2 months before the studies. Melatonin was administered [4 mg/kg, intraperitoneally (i.p.)] 1 hr before or 24 hr after the administration of a single dose of Dox (20 mg/kg, i.p.) and continued for 2 days. The levels of MDA Dox was found to be significantly higher in the Px rats (55.9 +/- 0.6 nmol/g tissue) than intact control animals (42.6 +/- 0.4). Dox administration to Px and non-Px rats significantly increased the MDA levels. Pre- and post-treatment with melatonin in both Px and intact rats significantly reduced MDA levels. Morphological changes parallelled the MDA alterations. These findings strongly suggest that both physiological and pharmacological concentrations of melatonin are important in protecting the heart from Dox-induced damage in rats. It would seem valuable to test melatonin in clinical trials for prevention of possible heart damage associated with Dox.
No takes yet. Share an insight, caveat, or question.
Şahna et al. (2003) studied Doxorubicin-induced cardiotoxicity. Melatonin vs. Sham-operated control / No melatonin was evaluated on Malondialdehyde (MDA) levels and morphological changes in heart. Melatonin reduced doxorubicin-induced malondialdehyde elevation and morphological heart damage in rats.
Synapse has enriched 10 related papers. Consider them for comparative context: